{"totalCount":3,"studies":[
{"protocolSection":{"identificationModule":{"nctId":"NCT07328451","orgStudyIdInfo":{"id":"DNLI-K-0001"},"secondaryIdInfos":[{"id":"2025-523515-11-00","type":"CTIS"}],"organization":{"fullName":"Denali Therapeutics Inc.","class":"INDUSTRY"},"briefTitle":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL628 in Participants With Early Alzheimer's Disease","officialTitle":"A Phase 1b, Multicenter, Randomized, Placebo-Controlled, Double-Blind Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL628 in Participants With Early Alzheimer's Disease"},"statusModule":{"statusVerifiedDate":"2026-02","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2026-01-30","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2027-02","type":"ESTIMATED"},"completionDateStruct":{"date":"2027-02","type":"ESTIMATED"},"studyFirstSubmitDate":"2025-12-24","studyFirstSubmitQcDate":"2025-12-24","studyFirstPostDateStruct":{"date":"2026-01-09","type":"ACTUAL"},"lastUpdateSubmitDate":"2026-02-20","lastUpdatePostDateStruct":{"date":"2026-02-23","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Denali Therapeutics Inc.","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":false,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This is a Phase 1b, multicenter, randomized, placebo-controlled, double-blind, multiple ascending dose (MAD) study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of DNL628 in participants with early Alzheimer's disease (AD), defined as mild cognitive impairment, or mild AD with biomarker evidence of amyloid positivity."},"conditionsModule":{"conditions":["Alzheimer Disease, Early Onset"],"keywords":["Alzheimer's Disease"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"SEQUENTIAL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"DOUBLE","maskingDescription":"Sponsor staff directly interacting with the site (clinical operations and medical monitor) will be blinded but may be unblinded if necessary to ensure participant safety.","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":68,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"Experimental Arm","type":"EXPERIMENTAL","interventionNames":["Drug: DNL628"]},{"label":"Placebo Arm","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"type":"DRUG","name":"DNL628","description":"Multiple ascending doses","armGroupLabels":["Experimental Arm"]},{"type":"DRUG","name":"Placebo","description":"Multiple ascending doses","armGroupLabels":["Placebo Arm"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Incidence and severity of treatment-emergent adverse events (TEAEs) throughout the double-blind period","timeFrame":"37 weeks"}],"secondaryOutcomes":[{"measure":"PK parameter: Maximum concentration (Cmax) of DNL628 in plasma","timeFrame":"37 weeks"},{"measure":"PK Parameter: Time to reach maximum concentration (tmax) of DNL628 in plasma","timeFrame":"37 weeks"},{"measure":"PK Parameter: Minimum concentration (Cmin) of DNL628 in plasma","timeFrame":"37 weeks"},{"measure":"PK Parameter: Area under the concentration-time curve (AUC) from time zero to time of last measurable concentration (AUClast) of DNL628 in plasma","timeFrame":"37 weeks"},{"measure":"PK Parameter: AUC from time 0 to the end of the dosing interval (AUCτ) of DNL628 in plasma","timeFrame":"37 weeks"},{"measure":"PK Parameter: terminal elimination half-life (t1/2) of DNL628 in plasma","timeFrame":"37 weeks"},{"measure":"PK Parameter: Accumulation ratio of DNL628 in plasma","timeFrame":"37 weeks"},{"measure":"Change from baseline in total tau and ptau181 as measured in CSF","timeFrame":"25 weeks"}]},"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\n* BMI of ≥18 to \\< 32 kg/m2 and body weight of ≥45 kg\n* Have a diagnosis of probable AD dementia based on NIA AA 2011 criteria, including amnestic or nonamnestic presentation at screening\n* Have supportive evidence of AD pathology via historical records or laboratory testing at screening for amyloid positivity\n* Have AD severity defined as the following at screening:\n\n  * A Clinical Dementia Rating global score of 0.5 or 1\n  * A Mini-Mental State Examination score of 20 to 30 (inclusive)\n\nKey Exclusion Criteria:\n\n* Have clinically significant neurological or cognitive disorders affecting the CNS other than AD, as determined by the investigator\n* Have clinically significant psychiatric conditions\n* Have any history of unstable or poorly controlled endocrine, pulmonary, cardiovascular, gastrointestinal, hepatic, hematological, or other significant medical condition that, in the opinion of the investigator, may interfere with the completion or interpretation of study assessment\n* Have had a malignancy within 5 years before screening, except fully resected basal cell carcinoma or other malignancies (such as prostate cancer) at low risk of recurrence, depending on investigator and medical monitor agreement\n* Have had previous anti amyloid or anti tau immunotherapy (including active immunization)\n\n  * Note: ADAD participants who have participated in previous passive anti-amyloid immunotherapy \\> 6 months previously will be allowed, contingent on investigator and Sponsor agreement\n* Have had previous exposure to gene therapy","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","maximumAge":"75 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Clinical Trials at Denali Therapeutics","role":"CONTACT","phone":"Email:","email":"clinical-trials@dnli.com"}],"overallOfficials":[{"name":"Medical Monitor","affiliation":"Denali Therapeutics","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Clinical Site(s)","status":"RECRUITING","city":"London","zip":"WC1N 3BG","country":"United Kingdom","geoPoint":{"lat":51.50853,"lon":-0.12574}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"},"conditionBrowseModule":{"meshes":[{"id":"D000544","term":"Alzheimer Disease"}],"ancestors":[{"id":"D003704","term":"Dementia"},{"id":"D001927","term":"Brain Diseases"},{"id":"D002493","term":"Central Nervous System Diseases"},{"id":"D009422","term":"Nervous System Diseases"},{"id":"D024801","term":"Tauopathies"},{"id":"D019636","term":"Neurodegenerative Diseases"},{"id":"D019965","term":"Neurocognitive Disorders"},{"id":"D001523","term":"Mental Disorders"}]}},"hasResults":false},
{"protocolSection":{"identificationModule":{"nctId":"NCT05262023","orgStudyIdInfo":{"id":"DNLI-H-0001"},"secondaryIdInfos":[{"id":"2023-508697-28-00","type":"CTIS"},{"id":"2021-005733-16","type":"EUDRACT_NUMBER"}],"organization":{"fullName":"Denali Therapeutics Inc.","class":"INDUSTRY"},"briefTitle":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia (FTD-GRN)","officialTitle":"A Phase 1/2, Multicenter, Randomized, Placebo-Controlled, Double Blind Single Dose and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DNL593 in Healthy Participants and Participants With Frontotemporal Dementia Followed by an Open-Label Extension"},"statusModule":{"statusVerifiedDate":"2026-01","overallStatus":"ACTIVE_NOT_RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2022-02-01","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-12","type":"ESTIMATED"},"completionDateStruct":{"date":"2028-11","type":"ESTIMATED"},"studyFirstSubmitDate":"2022-02-01","studyFirstSubmitQcDate":"2022-02-26","studyFirstPostDateStruct":{"date":"2022-03-02","type":"ACTUAL"},"lastUpdateSubmitDate":"2026-01-13","lastUpdatePostDateStruct":{"date":"2026-01-15","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Denali Therapeutics Inc.","class":"INDUSTRY"},"collaborators":[{"name":"Takeda","class":"INDUSTRY"}]},"oversightModule":{"oversightHasDmc":true,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false,"isUsExport":false},"descriptionModule":{"briefSummary":"This is a Phase 1/2, multicenter, randomized, placebo-controlled, double-blind study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of single and multiple doses of DNL593 in two parts followed by an optional open-label extension (OLE) period.\n\nPart A will evaluate the safety, tolerability, PK, and PD of single doses of DNL593 in healthy male and healthy female participants of nonchildbearing potential. Part B will evaluate the safety, tolerability, PK, and PD of multiple doses of DNL593 in participants with frontotemporal dementia (FTD) over 25 weeks. Part B will be followed by Part C, an optional 18-month OLE period available for all participants who complete Part B."},"conditionsModule":{"conditions":["Frontotemporal Dementia"],"keywords":["FTD","FTD-GRN","granulin"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE1","PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":85,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"DNL593 (Healthy Participant)","type":"EXPERIMENTAL","interventionNames":["Drug: DNL593"]},{"label":"Placebo (Healthy Participant)","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]},{"label":"DNL593 (Participants with FTD)","type":"EXPERIMENTAL","interventionNames":["Drug: DNL593"]},{"label":"Placebo (Participants with FTD)","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"type":"DRUG","name":"DNL593","description":"Ascending single doses (for healthy participants) and multiple doses (for participants with FTD)","armGroupLabels":["DNL593 (Healthy Participant)","DNL593 (Participants with FTD)"]},{"type":"DRUG","name":"Placebo","description":"Ascending single doses (for healthy participants) and multiple doses (for participants with FTD)","armGroupLabels":["Placebo (Healthy Participant)","Placebo (Participants with FTD)"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Incidence, severity, and seriousness of treatment-emergent adverse events (TEAEs)","timeFrame":"up to 18 months"},{"measure":"Incidence of treatment-emergent clinically significant abnormalities in safety laboratory values","timeFrame":"up to 18 months"},{"measure":"Change from baseline in vital sign measurements: systolic and diastolic blood pressure","timeFrame":"up to 18 months"},{"measure":"Change from baseline in vital sign measurements: heart rate","timeFrame":"up to 18 months"},{"measure":"Change from baseline in vital sign measurements: respiratory rate","timeFrame":"up to 18 months"},{"measure":"Change from baseline in vital sign measurements: body temperature","timeFrame":"up to 18 months"},{"measure":"Change from baseline in electrocardiogram (ECG) results including PR, QRS, and QTcF intervals","timeFrame":"up to 18 months"},{"measure":"Incidence of treatment-emergent clinically significant abnormalities in physical/neurological examination findings","timeFrame":"up to 18 months"},{"measure":"Change from baseline in Columbia-Suicide Severity Rating Scale (C-SSRS; Parts B and C only)","timeFrame":"up to 18 months"}],"secondaryOutcomes":[{"measure":"PK Parameter: Maximum concentration (Cmax) of DNL593 in serum","timeFrame":"up to 18 months"},{"measure":"PK Parameter: Time to reach maximum concentration (tmax) of DNL593 in serum","timeFrame":"up to 18 months"},{"measure":"PK Parameter: Area under the concentration-time curve (AUC) from time zero to time of last measurable concentration (AUClast) of DNL593 in serum","timeFrame":"up to 18 months"},{"measure":"PK Parameter: terminal elimination half-life (t1/2) of DNL593 in serum","timeFrame":"up to 18 months"},{"measure":"PK Parameter: AUC from time zero to infinity (AUC∞) of DNL593 in serum (Part A only)","timeFrame":"up to 84 days"},{"measure":"PK Parameter: Accumulation ratio of DNL593 in serum (Parts B and C only)","timeFrame":"up to 18 months"},{"measure":"PK Parameter: Trough concentration of DNL593 in serum (Ctrough) (Parts B and C only)","timeFrame":"up to 18 months"},{"measure":"PK Parameter: AUC from time 0 to the end of the dosing interval (AUCτ) of DNL593 in serum (Parts B and C only)","timeFrame":"up to 18 months"},{"measure":"Concentration of DNL593 in cerebrospinal fluid (CSF)","timeFrame":"up to 18 months"},{"measure":"DNL593 CSF:serum concentration ratio","timeFrame":"up to 18 months"},{"measure":"Percentage change from baseline in plasma NfL","timeFrame":"up to 18 months"}]},"eligibilityModule":{"eligibilityCriteria":"Key Inclusion Criteria:\n\nPart A:\n\n* Women of non-childbearing potential (surgically sterilized or post menopausal) or men, aged ≥18 to ≤ 55 years\n* BMI of ≥ 18 to ≤ 32 kg/m²\n* When engaging in sex with a woman of child bearing potential, two forms of birth control are required\n\nPart B:\n\n* Women of non-childbearing potential (surgically sterilized or post menopausal) or men, aged ≥18 to ≤ 80 years. Women who are of childbearing potential but on highly effective, low user dependent contraceptive methods will be allowed.\n* BMI of ≥ 18 to ≤ 32 kg/m²\n* Have a Clinical Dementia Rating® plus National Alzheimer's Coordinating Center frontotemporal lobar degeneration global score ≥ 0.5\n* Have confirmed granulin (GRN) mutation via genetic testing or historical records available for review by investigator\n* When engaging in sex with a woman of child bearing potential, both the male participant and his female partner must use highly effective contraception\n\nPart C:\n\n* All participants who completed Part B of this trial are eligible for an 18-month OLE if the participant has no unresolved clinically significant TEAEs, where continued dosing may represent a risk to participant safety.\n\nKey Exclusion Criteria:\n\n* Have any history of clinically significant neurologic, psychiatric, endocrine, pulmonary, cardiovascular, gastrointestinal, hepatic, pancreatic, renal, metabolic, hematologic, immunologic, or allergic disease, or other major disorders\n* Have a history of malignancy, except fully resected basal cell carcinoma or other malignancies at low risk of recurrence\n* Have a clinically significant history of stroke, cognitive impairment due to causes other than FTD, seizure within 5 years of screening, or head trauma with loss of consciousness within 2 years of screening\n* Have a positive serum pregnancy test or are currently lactating or breastfeeding","healthyVolunteers":true,"sex":"ALL","minimumAge":"18 Years","maximumAge":"80 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"overallOfficials":[{"name":"Amy Berger, MD","affiliation":"Denali Therapeutics Inc.","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"University of California San Francisco","city":"San Francisco","state":"California","zip":"94143","country":"United States","geoPoint":{"lat":37.77493,"lon":-122.41942}},{"facility":"John Hopkins University","city":"Baltimore","state":"Maryland","zip":"21218","country":"United States","geoPoint":{"lat":39.29038,"lon":-76.61219}},{"facility":"Hospital of the University of Pennsylvania","city":"Philadelphia","state":"Pennsylvania","zip":"19104","country":"United States","geoPoint":{"lat":39.95238,"lon":-75.16362}},{"facility":"University of Antwerp","city":"Antwerp","country":"Belgium","geoPoint":{"lat":51.22047,"lon":4.40026}},{"facility":"UZ Leuven","city":"Leuven","country":"Belgium","geoPoint":{"lat":50.87959,"lon":4.70093}},{"facility":"L2IP - Instituto de Pesquisas Clinicas LTDA","city":"Brasília","country":"Brazil","geoPoint":{"lat":-15.77972,"lon":-47.92972}},{"facility":"Faculdade de Medicina Da Universidade de São Paulo","city":"São Paulo","country":"Brazil","geoPoint":{"lat":-23.5475,"lon":-46.63611}},{"facility":"Hospital Universitario San Ignacio","city":"Bogotá","country":"Colombia","geoPoint":{"lat":4.60971,"lon":-74.08175}},{"facility":"Grupo de Neurosicencias de la Universidad de Antioquia","city":"Medellín","country":"Colombia","geoPoint":{"lat":6.245,"lon":-75.57151}},{"facility":"Fakultni nemocnice v Motole","city":"Prague","country":"Czechia","geoPoint":{"lat":50.08804,"lon":14.42076}},{"facility":"CHU de Nantes","city":"Nantes","country":"France","geoPoint":{"lat":47.21725,"lon":-1.55336}},{"facility":"CHU Rouen","city":"Rouen","country":"France","geoPoint":{"lat":49.44313,"lon":1.09932}},{"facility":"CHU Toulouse","city":"Toulouse","country":"France","geoPoint":{"lat":43.60426,"lon":1.44367}},{"facility":"ASST degli Spedali Civili di Brescia","city":"Brescia","country":"Italy","geoPoint":{"lat":45.53558,"lon":10.21472}},{"facility":"Azienda Ospedaliera Universitaria Careggi","city":"Florence","country":"Italy","geoPoint":{"lat":43.77925,"lon":11.24626}},{"facility":"IRCCS Istituto Auxologico Italiano","city":"Milan","country":"Italy","geoPoint":{"lat":42.78235,"lon":12.59836}},{"facility":"Azienda Ospedaliera Cardinale G Panico","city":"Tricase","country":"Italy","geoPoint":{"lat":39.93018,"lon":18.35421}},{"facility":"Erasmus University Medical Center","city":"Rotterdam","country":"Netherlands","geoPoint":{"lat":51.9225,"lon":4.47917}},{"facility":"Hospital de Braga","city":"Braga","country":"Portugal","geoPoint":{"lat":41.5514,"lon":-8.42311}},{"facility":"Campus Neurológico Sénior","city":"Torres Vedras","country":"Portugal","geoPoint":{"lat":39.09109,"lon":-9.2586}},{"facility":"Hospital Clinic de Barcelona","city":"Barcelona","state":"Barcelona","zip":"8036","country":"Spain","geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Hospital Universitario de Donostia","city":"Donostia / San Sebastian","state":"Guipúzcoa","zip":"20014","country":"Spain","geoPoint":{"lat":43.31283,"lon":-1.97499}},{"facility":"Hospital Universitario Virgen del Rocio","city":"Seville","state":"Sevilla","zip":"41013","country":"Spain","geoPoint":{"lat":37.38283,"lon":-5.97317}},{"facility":"Istanbul University Istanbul Medical Faculty","city":"Istanbul","country":"Turkey (Türkiye)","geoPoint":{"lat":41.01384,"lon":28.94966}},{"facility":"Ondokuz Mayis University Hospital","city":"Samsun","country":"Turkey (Türkiye)","geoPoint":{"lat":41.27976,"lon":36.3361}},{"facility":"Simbec Orion","city":"Merthyr Tydfil","state":"Wales","zip":"CF48 4DR","country":"United Kingdom","geoPoint":{"lat":51.74794,"lon":-3.37779}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25","removedCountries":["Serbia"]},"conditionBrowseModule":{"meshes":[{"id":"D057180","term":"Frontotemporal Dementia"}],"ancestors":[{"id":"D057174","term":"Frontotemporal Lobar Degeneration"},{"id":"D003704","term":"Dementia"},{"id":"D001927","term":"Brain Diseases"},{"id":"D002493","term":"Central Nervous System Diseases"},{"id":"D009422","term":"Nervous System Diseases"},{"id":"D057177","term":"TDP-43 Proteinopathies"},{"id":"D019636","term":"Neurodegenerative Diseases"},{"id":"D057165","term":"Proteostasis Deficiencies"},{"id":"D008659","term":"Metabolic Diseases"},{"id":"D009750","term":"Nutritional and Metabolic Diseases"},{"id":"D019965","term":"Neurocognitive Disorders"},{"id":"D001523","term":"Mental Disorders"}]}},"hasResults":false},
{"protocolSection":{"identificationModule":{"nctId":"NCT06602193","orgStudyIdInfo":{"id":"DNLI-C-0009"},"organization":{"fullName":"Denali Therapeutics Inc.","class":"INDUSTRY"},"briefTitle":"Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)","officialTitle":"A Phase 2a, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Pharmacodynamic Effects of BIIB122 in Participants With LRRK2-Associated Parkinson's Disease (LRRK2-PD)"},"statusModule":{"statusVerifiedDate":"2026-02","overallStatus":"RECRUITING","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2024-10-24","type":"ACTUAL"},"primaryCompletionDateStruct":{"date":"2026-04-30","type":"ESTIMATED"},"completionDateStruct":{"date":"2028-02-28","type":"ESTIMATED"},"studyFirstSubmitDate":"2024-09-16","studyFirstSubmitQcDate":"2024-09-16","studyFirstPostDateStruct":{"date":"2024-09-19","type":"ACTUAL"},"lastUpdateSubmitDate":"2026-02-16","lastUpdatePostDateStruct":{"date":"2026-02-18","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Denali Therapeutics Inc.","class":"INDUSTRY"},"collaborators":[{"name":"Biogen","class":"INDUSTRY"}]},"oversightModule":{"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false},"descriptionModule":{"briefSummary":"This Phase 2a, multicenter, randomized, 12-week double-blind, placebo-controlled, parallel-group study, followed by an OLE, is designed to evaluate the safety, tolerability, and pharmacodynamic effects of BIIB122 in participants with LRRK2-PD. LRRK2-PD is defined as Parkinson's Disease (PD) in individuals who are heterozygous or homozygous carriers of a pathogenic LRRK2 variant that increases LRRK2 kinase activity."},"conditionsModule":{"conditions":["Parkinson Disease"],"keywords":["LRRK2","Movement Disorders"]},"designModule":{"studyType":"INTERVENTIONAL","phases":["PHASE2"],"designInfo":{"allocation":"RANDOMIZED","interventionModel":"PARALLEL","primaryPurpose":"TREATMENT","maskingInfo":{"masking":"DOUBLE","whoMasked":["PARTICIPANT","INVESTIGATOR"]}},"enrollmentInfo":{"count":50,"type":"ESTIMATED"}},"armsInterventionsModule":{"armGroups":[{"label":"BIIB122 225 mg","type":"EXPERIMENTAL","description":"Oral 225 mg dose, once daily (QD)","interventionNames":["Drug: BIIB122 225 mg"]},{"label":"BIIB122 Matching Placebo","type":"PLACEBO_COMPARATOR","description":"Oral BIIB122 matching placebo, once daily (QD)","interventionNames":["Other: BIIB122-Matching Placebo"]}],"interventions":[{"type":"DRUG","name":"BIIB122 225 mg","description":"Administered as specified in the treatment arm","armGroupLabels":["BIIB122 225 mg"],"otherNames":["DNL151"]},{"type":"OTHER","name":"BIIB122-Matching Placebo","description":"Administered as specified in the treatment arm","armGroupLabels":["BIIB122 Matching Placebo"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) with BIIB122 compared with placebo over the 12-week double-blind period","timeFrame":"12 weeks"}],"secondaryOutcomes":[{"measure":"Change from baseline in whole-blood pS935 LRRK2 with BIIB122 compared with placebo at Week 12","timeFrame":"12 weeks"},{"measure":"Change from baseline in urine BMP with BIIB122 compared with placebo at Week 12","timeFrame":"12 weeks"}],"otherOutcomes":[{"measure":"Incidence of TEAEs and SAEs during the OLE period","timeFrame":"2.5 years"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* For heterozygous pathogenic LRRK2 mutation carriers: ≥ 30 to ≤ 80 years\n* For homozygous pathogenic LRRK2 mutation carriers: ≥ 30 years\n* Have screening genetic test results verifying the presence of a pathogenic LRRK2 variant.\n* Have a clinical diagnosis of PD meeting the Movement Disorder Society Clinical Diagnostic Criteria.\n\nExclusion Criteria:\n\n* Have a history of any clinically significant neurological disorder other than PD, including, but not limited to, stroke and dementia, in the opinion of the investigator, within 5 years of the screening visit.\n* Have clinical evidence of atypical parkinsonism (eg, multiple-system atrophy or progressive supranuclear palsy) or evidence of drug-induced parkinsonism.\n* Have previously participated or are currently participating in the BIIB122 LUMA study (Study 283PD201).\n* Have previously participated or are currently participating in a gene therapy study for PD.\n* Have a history of brain surgical intervention for PD (eg, deep-brain stimulation, pallidotomy).\n* Have any physical condition that may confound the motor assessment (MDS-UPDRS) over time (eg, severe arthritis, severe dyskinesias, traumatic injuries with permanent physical disability).\n* Abnormal vitals including Blood Pressure, Heart Rate, or Body Temperature\n* Have abnormal PFT results at screening\n\nNote: Other protocol defined Inclusion/Exclusion criteria may apply","healthyVolunteers":false,"sex":"ALL","minimumAge":"30 Years","stdAges":["ADULT","OLDER_ADULT"]},"contactsLocationsModule":{"centralContacts":[{"name":"Clinical Trials at Denali Therapeutics","role":"CONTACT","email":"clinical-trials@dnli.com"}],"overallOfficials":[{"name":"Danna Jennings, MD","affiliation":"Denali Therapeutics","role":"STUDY_DIRECTOR"}],"locations":[{"facility":"Cedars-Sinai Department of Neurology","status":"RECRUITING","city":"Los Angeles","state":"California","zip":"90048","country":"United States","contacts":[{"name":"Anne Tran","role":"CONTACT","phone":"310-423-1697","email":"anne.tran@cshs.org"},{"name":"Michele Tagliati, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":34.05223,"lon":-118.24368}},{"facility":"University of California San Francisco","status":"RECRUITING","city":"San Francisco","state":"California","zip":"94158","country":"United States","contacts":[{"name":"Luisa Bolo Dave","role":"CONTACT","email":"Luisa.Bolodave@ucsf.edu"},{"name":"Marta San Luciano Palenzuela, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":37.77493,"lon":-122.41942}},{"facility":"Parkinson's Disease and Movement Disorders Center","status":"RECRUITING","city":"Boca Raton","state":"Florida","zip":"33486","country":"United States","contacts":[{"name":"Stuart Isaacson, MD","role":"CONTACT","phone":"561-392-1818","email":"info@ParkinsonsCenter.org"},{"name":"Stuart Isaacson, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":26.35869,"lon":-80.0831}},{"facility":"Beth Israel Deaconess Medical Center","status":"RECRUITING","city":"Boston","state":"Massachusetts","zip":"02215","country":"United States","contacts":[{"name":"Jackie Forbes","role":"CONTACT","phone":"617-667-9885","email":"jforbes1@bidmc.harvard.edu"},{"name":"Ludy Shih, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":42.35843,"lon":-71.05977}},{"facility":"Ichan School of Medicine at Mount Sinai/Beth Israel Downtown-Movement Disorder Center","status":"RECRUITING","city":"New York","state":"New York","zip":"10003","country":"United States","contacts":[{"name":"Ricardo Renvill","role":"CONTACT","phone":"212-844-6055","email":"Ricardo.Renvill@mountsinai.org"},{"name":"Matthew Swan, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":40.71427,"lon":-74.00597}},{"facility":"Evergreen Health Laboratory","status":"RECRUITING","city":"Kirkland","state":"Washington","zip":"98034","country":"United States","contacts":[{"name":"EvergreenHealth Research Department","role":"CONTACT","email":"EvergreenResearch@evergreenhealthcare.org"},{"name":"Pinky Agarwal, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":47.68149,"lon":-122.20874}},{"facility":"Inland Northwest Research","status":"RECRUITING","city":"Spokane","state":"Washington","zip":"99202","country":"United States","contacts":[{"name":"Jason Aldred, MD","role":"CONTACT","phone":"509-960-2818","email":"jaldred@selkirkneurology.com"},{"name":"Jason Aldred, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":47.65966,"lon":-117.42908}},{"facility":"Technische Universität Dresden","status":"RECRUITING","city":"Dresden","country":"Germany","contacts":[{"name":"Marian Kollaske","role":"CONTACT","email":"Marian.Kollaske@ukdd.de"},{"name":"Björn Falkenburger, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":51.05089,"lon":13.73832}},{"facility":"University of Lübeck","status":"RECRUITING","city":"Lübeck","country":"Germany","contacts":[{"name":"Madita Grümmer","role":"CONTACT","email":"madita.gruemmer@uni-luebeck.de"},{"name":"Norbert Brüggemann, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":53.86893,"lon":10.68729}},{"facility":"University Hospital Tübingen","status":"RECRUITING","city":"Tübingen","country":"Germany","contacts":[{"name":"Susanne Solbrig","role":"CONTACT","email":"Susanne.Solbrig@med.uni-tuebingen.de"},{"name":"Thomas Gasser, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":48.52266,"lon":9.05222}},{"facility":"Rabin Medical Center","status":"RECRUITING","city":"Petah Tikva","country":"Israel","contacts":[{"name":"Dana Vhava","role":"CONTACT","email":"danavh@clalit.org.il"},{"name":"Ruth Djaldetti, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":32.08707,"lon":34.88747}},{"facility":"Movement Disorders Institute, Sheba Medical Center","status":"RECRUITING","city":"Ramat Gan","country":"Israel","contacts":[{"name":"Adi Saar","role":"CONTACT","email":"adi.saar@sheba.health.gov.il"},{"name":"Sharon Hassin, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":32.08227,"lon":34.81065}},{"facility":"Tel Aviv Medical Center","status":"RECRUITING","city":"Tel Aviv","country":"Israel","contacts":[{"name":"Adi Ezra","role":"CONTACT","email":"adil@tlvmc.gov.il"},{"name":"Tanya Gurevich, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":32.08088,"lon":34.78057}},{"facility":"Hospital Clinic de Barcelona","status":"RECRUITING","city":"Barcelona","country":"Spain","contacts":[{"name":"Pilar Santacruz","role":"CONTACT","email":"PSANTA@clinic.cat"},{"name":"Alicia Garrido, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Hospital Universitari General de Catalunya","status":"RECRUITING","city":"Barcelona","country":"Spain","contacts":[{"name":"Susana Andrade","role":"CONTACT","phone":"+3493175715","email":"s.andrade@udic.es"},{"name":"Ernest Balaguer Martínez, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Hospital Universitari Vall d'Hebron","status":"RECRUITING","city":"Barcelona","country":"Spain","contacts":[{"name":"Alejandra Garcia Blanco","role":"CONTACT","email":"alejandra.garcia@vhir.org"},{"name":"Jorge Hernandez-Vara, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":41.38879,"lon":2.15899}},{"facility":"Hospital Universitario Donostia","status":"RECRUITING","city":"Donostia / San Sebastian","country":"Spain","contacts":[{"name":"Ioana Croitoru","role":"CONTACT","email":"ioana.croitoru@bio-gipuzkoa.eus"},{"name":"Javier Ruiz Martinez, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":43.31283,"lon":-1.97499}},{"facility":"Universitary Hospital La Princesa","status":"RECRUITING","city":"Madrid","country":"Spain","contacts":[{"name":"Pablo Sáinz-Ezquerra","role":"CONTACT","email":"p.sainzezquerra@gmail.com"},{"name":"Lydia Lopez-Manzares, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":40.4165,"lon":-3.70256}},{"facility":"IDIVAL/University Hospital Marques de Valdecilla","status":"RECRUITING","city":"Santander","country":"Spain","contacts":[{"name":"Raquel Martinez","role":"CONTACT","email":"raquel.martinez@scsalud.es"},{"name":"Jon Infante, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":43.46589,"lon":-3.80493}},{"facility":"Hospital Universitario Virgen del Rocio","status":"RECRUITING","city":"Seville","country":"Spain","contacts":[{"name":"Cristina Gomez Rapela","role":"CONTACT","email":"cgomez-ibis@us.es"},{"name":"Lorena Garrote","role":"CONTACT","email":"lgarrote-ibis@us.es"},{"name":"Pablo Mir Rivera, MD","role":"PRINCIPAL_INVESTIGATOR"}],"geoPoint":{"lat":37.38283,"lon":-5.97317}}]},"ipdSharingStatementModule":{"ipdSharing":"NO"}},"derivedSection":{"miscInfoModule":{"versionHolder":"2026-02-25"},"conditionBrowseModule":{"meshes":[{"id":"D010300","term":"Parkinson Disease"},{"id":"D009069","term":"Movement Disorders"}],"ancestors":[{"id":"D020734","term":"Parkinsonian Disorders"},{"id":"D001480","term":"Basal Ganglia Diseases"},{"id":"D001927","term":"Brain Diseases"},{"id":"D002493","term":"Central Nervous System Diseases"},{"id":"D009422","term":"Nervous System Diseases"},{"id":"D000080874","term":"Synucleinopathies"},{"id":"D019636","term":"Neurodegenerative Diseases"}]},"interventionBrowseModule":{"meshes":[{"id":"C000730636","term":"DNL151"}]}},"hasResults":false}
]}